What problem does this paper attempt to address?

The paper attempts to address the role of a key enzyme, acetyl-CoA carboxylase 1 (ACACA), in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD). Specifically, the study aims to explore the role of ACACA in regulating lipid metabolism and mitochondrial function, and the mechanism by which it reduces lipid accumulation through the AMPK-PPARα-CPT1A axis. ### Research Background - **NAFLD** is a complex metabolic disease characterized by excessive lipid accumulation in hepatocytes, which can lead to non-alcoholic steatohepatitis (NASH), and even liver failure and hepatocellular carcinoma (HCC). - The global prevalence of NAFLD is rapidly increasing, associated with the increased intake of high-fat diets (HFD). - **ACACA** is a key enzyme controlling fatty acid synthesis, and its increased activity can promote adipocyte differentiation and fat accumulation. ### Research Objectives - **Investigate the role of ACACA in the occurrence and development of NAFLD**: By establishing a high-fat diet-induced mouse model of fatty liver, analyze the transcriptome data of liver samples to determine the function of ACACA in NAFLD. - **Study the impact of ACACA on lipid metabolism and mitochondrial function**: By inhibiting the expression of ACACA, observe its effects on lipid accumulation, mitochondrial function, and oxidative stress. - **Elucidate the mechanism by which ACACA regulates lipid metabolism and mitochondrial function through the AMPK-PPARα-CPT1A axis**: Through in vivo and in vitro experiments, verify the impact of ACACA inhibition on the AMPK-PPARα-CPT1A signaling pathway. ### Main Findings - **High-fat diet significantly increased the body weight, liver weight, and intrahepatic lipid accumulation in mice**, leading to the occurrence and development of NAFLD. - **ACACA was significantly upregulated in the high-fat diet-induced fatty liver model**, and gradually increased over time. - **Inhibition of ACACA can reduce intracellular lipid accumulation**, lowering the content of TG and TC. - **ACACA inhibition can improve mitochondrial function**, including restoring mitochondrial membrane potential (MMP), increasing ATP production, and reducing reactive oxygen species (ROS) production. - **ACACA inhibition enhances lipid metabolism by activating the AMPK-PPARα-CPT1A axis**, promoting the β-oxidation of free fatty acids, thereby reducing intracellular lipid accumulation. ### Conclusion - **Targeting ACACA can reduce lipid accumulation by mediating the AMPK-PPARα-CPT1A pathway**, regulate lipid metabolism, and alleviate mitochondrial dysfunction, providing a new potential target for the treatment of NAFLD. ### Keywords - **NAFLD** - **ACACA** - **Mitochondrial dysfunction** - **AMPK/PPARα/CPT1A** Through these studies, the authors provide new insights into the pathogenesis of NAFLD and lay the foundation for developing therapeutic strategies targeting ACACA.

ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis

N-Acetyl Cysteine Ameliorates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Intracellular Triglyceride Accumulation by Preserving Mitochondrial Function

LncNONMMUG027912 alleviates lipid accumulation through AMPKα/mTOR/SREBP1C axis in nonalcoholic fatty liver

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

The AMPK pathway in fatty liver disease

AMPKα1 Overexpression Alleviates the Hepatocyte Model of Nonalcoholic Fatty Liver Disease Via Inactivating P38mapk Pathway.

Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance

Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease

Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice

AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression

Inhibition of fatty acid translocase (FAT/CD36) palmitoylation enhances hepatic fatty acid β-oxidation by increasing its localization to mitochondria and interaction with long-chain acyl-CoA synthetase 1.

High Fat Activates O-GlcNAcylation and Affects AMPK/ACC Pathway to Regulate Lipid Metabolism

Pharmacological Activation of AMPK Prevents Drp1-mediated Mitochondrial Fission and Alleviates Hepatic Steatosis In vitro

Citrus maxima and tea regulate AMPK signaling pathway to retard the progress of nonalcoholic fatty liver disease

3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways

Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function

Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD

Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice

Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway

Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice

Caveolin-1 Alleviates Acetaminophen-Induced Fat Accumulation in Non-Alcoholic Fatty Liver Disease by Enhancing Hepatic Antioxidant Ability via Activating AMPK Pathway